1. What regimen is considered preferred for front-line unresectable or metastatic cholangiocarcinoma?

2. Which of the following best characterizes the use of second-line therapy in unresectable or metastatic cholangiocarcinoma?

3. What are potential adherence barriers to pemigatinib therapy?

« Return to Activity